RUCONEST® is indicated for treatment of acute HAE attacks in children ≥2 years with HAE due to C1-INH deficiency2**
95.9% (70/73, N=20) of attacks in children aged 5-14 years were treated with a single dose of RUCONEST®1
Median time to onset of symptom relief was 60 minutes1
No treatment-related SAEs or hypersensitivity reactions were reported1
Incidence of AEs in patients treated for >1 attack did not increase1
*RUCONEST® has an established safety profile in children with HAE >5 years of age.
**RUCONEST® is licensed for children 2 years and above with limited data available for children aged between 2-5 years.²
AE: adverse event; HAE: hereditary angioedema; SAE: serious adverse event; SmPC: Summary of Product Characteristics.
Fast, effective, sustained relief in one dose regardless of attack location or severity5-7
A RUCONEST® vial has a shelf life of 4 years, at room temperature, making it convenient for storing at the hospital2
Established safety profile for adults and children ≥5 years1,2
C1 esterase inhibitor (C1-INH) returned to normal levels* in 94% of patients, regardless of age or weight, with just one dose**3
*The normal range of plasma C1-INH in healthy individuals is between 0.70–1.30 U/mL.⁸
**Dosing of RUCONEST® is weight dependent and one dose is, therefore, based on patient weight as follows; <84 kg: 50 U/kg (1–2 vials); ≥84 kg: fixed dose of 2 vials (4200 U).²
Identical amino acid sequence to native human C1-INH9
Rapid onset of action6,7
96% of patients experience relief with just one dose5,8
One dose stops attacks for at least 3 days in 93% of patients4
RUCONEST® is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
Sign-up to get access to hear from experts in the field, watch webinar broadcasts and receive RUCONEST® related information and news.Subscribe